Male Hypogonadism - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463974 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Male Hypogonadism - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H2 2019, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 3, 7, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).

- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Male Hypogonadism - Overview

Male Hypogonadism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Male Hypogonadism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Male Hypogonadism - Companies Involved in Therapeutics Development

Allergan Plc

Diurnal Group Plc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

TesoRx Pharma LLC

Viramal Ltd

Male Hypogonadism - Drug Profiles

chorionic gonadotropin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corifollitropin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leflutrozole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPCN-1111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Block VDAC1 for Hypogonadism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rifene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-722 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Male Hypogonadism - Dormant Projects

Male Hypogonadism - Discontinued Products

Male Hypogonadism - Product Development Milestones

Featured News & Press Releases

Nov 01, 2019: Acerus provides update on temporary unavailability of NATESTO in Canada and South Korea

Oct 23, 2019: Acerus Pharma hosting key opinion leader meeting on unique clinical evidence of NATESTO for treatment of Hypogonadism

Oct 17, 2019: New data demonstrates that Natesto increases serum testosterone and improves symptoms while maintaining normal semen parameters in men with low testosterone through six months

Oct 16, 2019: Aytu BioScience to announce results from Natesto spermatogenesis study on Thursday, October 17

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463974 | GMDHC11409IDB

Number of Pages

103

Report Format

PDF

Related Reports

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Male Hypogonadism - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.